

AMENDED CLAIMS

[received by the International Bureau on 28 April 2005 (28.04.05);
Claim 109 amended (2 pages)]

103. Use of a transfection complex or viral vector as claimed in any one of claims 65 to 75, 79 to 81 and 83 to 96 for the manufacture of a medicament for the prophylaxis of a condition caused in a human or a non-human animal by a defect and/or a deficiency in a gene, or for therapeutic or prophylactic immunisation, or for anti-sense therapy.

104. A kit that comprises

- (i) a nucleic acid,
- (ii) a lipid component,
- (iii) a polycationic nucleic acid-binding component, and
- (iv) a peptide as claimed in any one of claims 1 to 34, which peptide is not subject to the proviso of claim 1.

105. A kit that comprises

- (i) a nucleic acid,
- (iii) a polycationic nucleic acid-binding component, and
- (iv) a peptide as claimed in any one of claims 1 to 34, which peptide is not subject to the proviso of claim 1.

20

106. A bispecific antibody that is capable of binding to a virus and to a peptide as claimed in any one of claims 1 to 34.

25 107. A fusion protein that comprises a peptide as claimed in any one of claims 1 to 34, which peptide is not subject to the proviso of claim 1, and antibody that is capable of binding to a virus.

30 108. A method for identifying an siRNA, which comprises transfecting a cell that expresses a target gene with the siRNA and quantifying expression levels.

35 109. A peptide having the sequence DWWHTSA [SEQ.ID.NO.:28] or SHVKLNS [SEQ.ID.NO.:29] or QLLTGAS [SEQ.ID.NO.:30] or

TARDYRL [SEQ.ID.NO.:31] or FPRAPHH [SEQ.ID.NO.:32] or SEWLSAL [SEQ.ID.NO.:33] or IGGIRRH [SEQ.ID.NO.:34] or YTMEFNR [SEQ.ID.NO.:35] or MASISMK [SEQ.ID.NO.:27] or PAAYKAH [SEQ.ID.NO.:36].